Clinical Trials | December 04, 2025
Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis
The company is excluding data from the affected sites to maintain the study's integrity
The company is excluding data from the affected sites to maintain the study's integrity
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Subscribe To Our Newsletter & Stay Updated
